Trial Profile
A 24-week phase III study to evaluate the efficacy and tolerability of beclometasone/formoterol single inhaler HFA [hydrofluoroalkane] 134a-pMDI [pressurised meter dose inhalers] in adult patients with moderate to severe persistent asthma.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Beclometasone/formoterol (Primary) ; Beclometasone; Formoterol
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Chiesi Farmaceutici
- 01 Jan 2009 Results were published in Repiratory Medicine in Jan 2009.
- 21 Jul 2007 New trial record.